Darrell Tan




Dr. Darrell Tan is an infectious diseases physician, clinician-scientist and Canadian Institutes of Health Research (CIHR) New Investigator whose research focuses on clinical trials in human immunodeficiency virus (HIV) prevention and HIV/sexual transmitted infection (STI) co-infection. As Director of the University of Toronto Clinical Research Unit on HIV Prevention and co-leader of the CIHR Canadian HIV Trials Network Biomedical Prevention Working Group, he is leading multiple efforts to optimize the implementation of HIV pre- and post-exposure prophylaxis (PrEP and PEP) in Canada. These include Canada’s first demonstration project of daily oral TDF/FTC-based PrEP in Toronto MSM, the development of national Clinical Practice Guidelines on PEP & PrEP use, exploration of the relationship between syndemic health problems and clinical outcomes of PEP & PrEP, studies of nurse-led PEP & PrEP, and evaluations of novel antiretroviral PEP regimens.

Additional research interests are in the interaction between HIV and common co-infections such as herpes simplex virus type 2 (HSV-2) and syphilis, and the role of systemic inflammation in driving clinical outcomes in people living with HIV. He is also Co-Principle Investigator on two CIHR-supported multicentre randomized control trials including the a trial of anti-herpes medication for attenuating HIV disease progression, and a trial of enhanced syphilis screening in HIV-positive men.

Recent Publications

  1. Sinno, J, Doria, N, Cochkanoff, N, Numer, M, Neyedli, H, Tan, D et al.. Attitudes and Practices of a Sample of Nova Scotian Physicians for the Implementation of HIV Pre-Exposure Prophylaxis. HIV AIDS (Auckl). 2021;13 :157-170. doi: 10.2147/HIV.S287201. PubMed PMID:33574712 PubMed Central PMC7872901.
  2. Feld, JJ, Kandel, C, Biondi, MJ, Kozak, RA, Zahoor, MA, Lemieux, C et al.. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021; :. doi: 10.1016/S2213-2600(20)30566-X. PubMed PMID:33556319 PubMed Central PMC7906707.
  3. Wang, L, Moqueet, N, Simkin, A, Knight, J, Ma, H, Lachowsky, NJ et al.. Mathematical modelling of the influence of serosorting on the population-level HIV transmission impact of pre-exposure prophylaxis. AIDS. 2021; :. doi: 10.1097/QAD.0000000000002826. PubMed PMID:33534205 .
  4. Cheng, MP, Lee, TC, Tan, DHS, Murthy, S. CMAJ. 2020;192 (42):E1296-E1298. doi: 10.1503/cmaj.200438-f. PubMed PMID:33077531 PubMed Central PMC7588204.
  5. Rana, J, Guiang, CB, Lisk, R, Shahin, R, Brunetta, J, Mitterni, L et al.. Survey of Health Care Providers' Practices and Opinions Regarding Bacterial Sexually Transmitted Infection Testing Among Gay, Bisexual, and Other Men Who Have Sex With Men. Sex Transm Dis. 2021;48 (2):94-102. doi: 10.1097/OLQ.0000000000001287. PubMed PMID:33003183 .
  6. Tan, DHS, Agrawal, R, Barnabas, RV, Giles, JT, Dull, P. Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxis. Trials. 2020;21 (1):815. doi: 10.1186/s13063-020-04754-9. PubMed PMID:32993804 PubMed Central PMC7523255.
  7. Wright, JK, Tan, DHS, Walmsley, SL, Hulme, J, O'Connor, E, Snider, C et al.. Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada. Trials. 2020;21 (1):647. doi: 10.1186/s13063-020-04577-8. PubMed PMID:32665039 PubMed Central PMC7359423.
  8. Tan, DHS, Dashwood, TM, Wilton, J, Kroch, A, Gomes, T, Martins, D et al.. Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018). Can J Public Health. 2021;112 (1):89-96. doi: 10.17269/s41997-020-00332-3. PubMed PMID:32529552 PubMed Central PMC7851246.
  9. Clifford-Rashotte, M, Fawcett, N, Fowler, B, Reinhart, J, Tan, DHS. Assessing the Potential for Nurse-Led HIV Pre- and Postexposure Prophylaxis in Ontario. Can J Nurs Res. 2020; :844562120924269. doi: 10.1177/0844562120924269. PubMed PMID:32380845 .
  10. Cheng, MP, Lee, TC, Tan, DHS, Murthy, S. Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. CMAJ. 2020;192 (15):E405-E407. doi: 10.1503/cmaj.200438. PubMed PMID:32336678 PubMed Central PMC7162442.
Search PubMed

Affiliations & Other Activities

  • Clinician-Scientist, Department of Medicine, St. Michael’s Hospital
  • Assistant Professor, Department of Medicine, University of Toronto
  • Assistant Professor, Institute of Health Policy, Management & Evaluation, University of Toronto
  • Director, HIV Prevention Clinical Research Unit, University of Toronto
  • Affiliate Scientist, Toronto General Research Institute